Sana CEO Steve Harr Details Cell- and Gene-Therapy Plans After $700M+ Summer Raise
Sana Biotechnology CEO Steve Harr described the stealthy, Seattle-based gene and cell therapy startup’s plan to develop tools that repair and replace human cells to treat diseases and create new medicines, after raising more than $700 million this summer. Founded in 2019 by former Juno Therapeutics executives, the 250-person company emphasizes faster decision-making, focus, and communication as its competitive edge against larger rivals.
No comments yet.